Detecting HPV DNA in Anal and Cervical Cancers
Recruiting · NCT04857528 · Observational (researchers observe without assigning treatment) · Lead sponsor: University of Chicago
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
This is a research study for individuals who have cancer associated with human papillomavirus (HPV) and are being treated with radiation as part of standard care for their cancer. Doctors leading this study will use blood tests to find out if they can detect the HPV virus in the blood of study participants before, during, and after radiation treatment. They will also collect blood and archival tumor tissue (from a previous biopsy) to perform other tests in the future that could provide more information about HPV-associated cancers and how they respond to treatment. Participation in this study will last approximately 2 years.
Who can take part
Inclusion criteria
- Stage I-III anal cancer or stage I-IVA cervical cancer that is p16+ based on immunohistochemistry.
- Age ≥ 18 years
- Planned to undergo radiation therapy as definitive treatment, with or without concurrent systemic therapy
Exclusion criteria
- Anal carcinoma not associated with HPV-16, 18, 31, 33, or 35 will be removed from the
- Planned to undergo radiation therapy as an adjuvant or post-operative therapy
Where it is running
2 locations listed across 1 US state.
- University of Illinois at Chicago - Chicago, Illinois, United States
- University of Chicago - Chicago, Illinois, United States